The European Commission is being requested to deliver an extensive examination of the current state within the country.

The European Commission is being requested to deliver an extensive examination of the current state within the country.

Stock Market Surges, Semiconductors Shine

Kickstarting the Week on a Strong NoteThe US stock markets are off to a solid start in the new trading week, brushing aside recent geopolitical turbulence in the Middle East. The oil market has simmered down following significant increases, but the semiconductor sector is creating a real stir.

Semiconductors Gain TractionAMD, the semiconductor powerhouse, is showing signs of a comeback on the stock market. Its stock soared by approximately 10%, edging closer to its yearly high, thanks to a positive analyst assessment from Piper Sandler. Companies like Marvell Technology, ARM, and Micron also enjoyed noteworthy increases in their stock values.

Dow Jones: Mixed SignalsCisco benefited from an upgrade to "Buy" by Deutsche Bank, as analysts praised the stock's appealing valuation for 2026. However, UnitedHealth's stock was once again a major loser, slipping without any corporate or analyst news, with the healthcare sector overall faltering on Monday.

• AMD: Riding the Waves - Semiconductors on the Rise

In the world of semiconductors, AMD is making headway, fueled by positive industry trends and favorable analyst opinions. Here's a closer look:

1. Current Price and Future Outlook: As of mid-2025, AMD's stock price is hovering around $162.21, reflecting substantial growth from the year's beginning[5]. Analysts forecast further growth, with the stock expected to touch $265 by the year's end, representing a 63% increase from the current levels[5].
2. Analyst Consensus: The analyst consensus for AMD is Moderate Buy, based on 22 'Buy' recommendations and 11 'Holds', with no 'Sells' in the past three months[4]. This indicates a generally positive forecast for AMD's stock.
3. Long-term Predictions: Long-term forecasts predict that AMD's stock price could climb to $150 by mid-2026 and $200 by the year's end[5]. Beyond that, predictions suggest continued growth, with possible prices exceeding $500 by the mid-2030s[5].

Biotech Sector: Sarepta Therapeutics StrugglesSarepta Therapeutics, a US biotech company, continues to draw attention in the biotech sector due to a series of unfortunate events. The firm has reported another death linked to its gene therapy, Eteplirsen (outside the US, Roche holds the rights for Duchenne muscular dystrophy treatment). The stock dived more than 40% and reached a new multi-year low.

Wall Street: Recovery ExpectedAttention will soon shift to the Fed's monetary policy meeting as the geopolitical situation in the Middle East fades into the background. DER AKTIONÄR will keep you updated on the most relevant market news.

• Wall Street: Recovery Expected
• Sarepta Stock Plummets: More Trouble on the Horizon
• Sarepta Therapeutics: Weak Performance Continues
• UnitedHealth Stock Under Pressure Again
• AMD Stock Surges Amid Positive Financial Outlook and Technology AdvancementsWith the semiconductor sector creating a real stir in the stock-market, AMD, a leading player, is winning accolades. The tech giant's stock soared by approximately 10%, edging closer to its yearly high, fueled by positive financial forecasts and industry advancements.
• Sarepta Therapeutics Faces Challenges as Technology Sector ThrivesIn contrast to the technology sector's rising tide, Sarepta Therapeutics, a US biotech company, is struggling. The company's stock dived more than 40% following a series of unfortunate events, further distancing itself from the sector's growth.

Read also: